Author: Customer Service

Turing Award Laureate Joseph Sifakis Visits CaoCao AI Innovation Center, Witnesses Launch of Trustworthy AI Research Project for Robotaxi Curbside Operations

Written by Customer Service on October 23, 2026. Posted in Public Companies.

SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) — On October 21, Professor Joseph Sifakis, a Turing Award laureate and Chief Scientific Advisor of the CaoCao Mobility AI Innovation Research Center, visited the center for in-depth discussions with CaoCao’s technology team. On the same day, CaoCao launched a research project on Trustworthy Decision-Making and Multi-Agent Coordination for Robotaxi Curbside Operations. Professor Sifakis witnessed the launch and offered valuable recommendations based on his extensive research experience.Professor Sifakis is one of the pioneers of model checking. He received the 2007 Turing Award for his contributions to the development of model-checking theory and its applications. He has long been engaged in research on complex intelligent systems and Trustworthy Autonomous Systems, areas closely...

ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026

Written by Customer Service on October 23, 2026. Posted in Public Companies.

Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED inhibitor rinzimetostat maintained effectiveness Preclinical results, supported by translational data in mCRPC patient samples, show rinzimetostat reinforces a luminal, AR-dependent state, restricts lineage plasticity and enhances sensitivity to AR inhibition Findings reinforce rinzimetostat’s differentiated profile and support development across the prostate cancer disease spectrum, including in the ongoing Himalayas-1 Phase 3 trial SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments...

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

Written by Customer Service on October 23, 2026. Posted in Public Companies.

In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses 88% 6-month landmark PFS compares favorably to current standards of care and to investigational therapies; follow-up ongoing with majority of patients continuing on treatment Competitive safety profile with no significant off-target toxicity and no treatment-related discontinuations Redwood-1 global Phase 3 registrational trial initiation in 1L EGFR atypical NSCLC expected in 1H 2027 Company to host a conference call and webcast today at 8:00 am ET featuring Dr. Joshua Sabari SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,...

NOTICE OF GENERAL MEETING OF SHAREHOLDERS OF ECONOCOM SE OF 24 NOVEMBER 2026

Written by Customer Service on October 23, 2026. Posted in Public Companies.

The shareholders are invited to attend the general meeting of Econocom Group SE, with registered office at Place du Champ de Mars 5, 1050 Brussels, Belgium, registered with the Crossroads Bank for Enterprises under number 0422.646.816 (the “Company“), to be held on Tuesday 24 November 2026 at 2 p.m. (Belgian time) at the Company’s registered office (the “Meeting“). AGENDA AND PROPOSED RESOLUTIONS FOR THE GENERAL MEETINGAppointment of Ms. Véronique Torner as independent directorProposed resolution:Proposal to appoint Ms. Véronique Torner as independent director of the Company for a term of 4 (four) years, with immediate effect and ending at the close of the annual general meeting to be held in 2030. Ms. Véronique Torner meets the independence criteria set out in Article 7:87 of the Code on companies and...

AS Tallinna Vesi will hold an Investor Conference Webinar to introduce the results for the 3rd quarter of 2026

Written by Customer Service on October 23, 2026. Posted in Earnings Releases And Operating Results.

AS Tallinna Vesi invites its shareholders, investors, analysts, and other stakeholders to join its investor conference webinar, introducing the results for the 3rd quarter and 9 months of 2026. The webinar is scheduled for 30 October 2026 at 11:00 am (EET) and will be held in English. The webinar will be hosted by Aleksandr Timofejev, Chief Executive Officer, and Taavi Gröön, Chief Financial Officer. The questions will be answered by Aleksandr Timofejev and Taavi Gröön after the presentation. We encourage participants to send their questions before the webinar takes place, by 9:00 am (EET) on 30 October at the latest, to kommunikatsioon@tvesi.ee. Questions can also be asked during the webinar. To join the webinar, please register via following link. The registration will be open until 30 October at 9:00 am (EET). You will receive a link...

Bank of Åland Plc: Interim Report for the period January – September 2026

Written by Customer Service on October 23, 2026. Posted in Earnings Releases And Operating Results.

Bank of Åland PlcInterim ReportOctober 23, 2026 9.00 EEST Interim Report for the period January – September 2026 Continued solid development in the core business “Our business continues to perform well, and we generated a return on equity of 16.9 per cent during the quarter. “The volume of actively managed assets that we manage on behalf of our customers continued to record strong net inflows and reached a new all-time high of EUR 12.5 billion. Our three main segments, Private Banking, Premium Banking and IT, together improved their results compared with the corresponding period last year. “We received confirmation of our strong customer relationships in EPSI Rating’s customer survey of the Finnish banking and finance sector, in which the Bank of Åland received the sector’s highest ratings for service, quality, customer loyalty,...

SATO Corporation Interim Report 1 January–30 September 2026: Occupancy rate increased due to strong operational performance

Written by Customer Service on October 23, 2026. Posted in Earnings Releases And Operating Results.

SATO Corporation, Interim Report 23 October 2026 at 9:00 am EET This is a summary of SATO’s interim report for January–September, which has been published in full as an appendix to the release and at www.sato.fi/en. The figures in the report are unaudited. Summary for 1 Jan – 30 Sep 2026 (1 Jan – 30 Sep 2025)The economic occupancy rate was 95.5% (95.2). Net sales totalled EUR 244.1 million (235.5). Net rental income was EUR 169.1 million (166.2). Profit before taxes was EUR 69.2 million (80.3). The unrealised change in the fair value of investment properties included in the result was EUR -4.1 million (7.3). Housing investments amounted to EUR 131.6 million (219.4). Invested capital at the end of the review period was EUR 4,945.2 million (4,864.2). Return on invested capital was 3.7% (4.0). Equity was EUR 2,727.0 million (2,663.3) or...

JLT Mobile Computers AB (publ) publishes interim report for January–September 2026

Written by Customer Service on October 23, 2026. Posted in Earnings Releases And Operating Results.

Växjö, Sweden, 23 October 2026 * * * JLT Mobile Computers, a leading supplier of rugged computers for demanding environments, publishes its interim report for the period January–September 2026 today. Summary of key figures July–Sept January–SeptOrder Intake, MSEK 15.2 (30.1) 64.9 (111.6)Net Sales, MSEK 16.9 (28.2) 75.1 (104.0)Operating Profit, MSEK -4.5 (1.6) -5.9 (1.1)Profit after taxes, MSEK -4.6 (1.3) -6.8 (0.9)Cashflow, MSEK 2.5 (8.1) -7.2 (2.9)CEO comments The period was characterized by weak demand, particularly in our largest segment, warehousing and logistics. This development was primarily attributable to component shortages and sharply higher prices, combined with geopolitical uncertainty and elevated energy costs. In some cases, memory prices increased by as much as 15 times as suppliers prioritized...

Ipsos: Organic growth of 2.0% in Q3

Written by Customer Service on October 23, 2026. Posted in Earnings Releases And Operating Results.

Organic growth of 2.0% in Q3 2026 organic growth guidance updatedAcceleration of Horizons deployment Paris, 23 October 2026 – Ipsos, one of the world’s leading market research and opinion polling companies, generated revenue of €636.2 million in Q3. Organic growth reached 2.0% in the quarter, compared with 0.8% in the first half, driven notably by good performances in EMEA, China and our Citizens business. For the first nine months of the year, revenue increased by 0.9%, with organic growth reaching 1.2%. Scope effects contributed 1.6%, reflecting the acquisition of The BVA Family, partially offset by the deconsolidation of Russia. Currency effects stood at -1.9%, primarily due to the appreciation of the euro against the US dollar. 2026 Revenuein € million 2025 Revenuein € million Total growth Organic growth1st quarter 554.9 568.5 -2.4% -1.4%2nd...

IBA signs major contract for a high-throughput Be Efficient sterilization solution in Germany

Written by Customer Service on October 23, 2026. Posted in Public Companies.

Louvain-la-Neuve, Belgium, October 23, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial irradiation, announced today that it has signed a contract with an undisclosed customer for the delivery of a fully integrated Be Efficient electron beam (E-beam) sterilization solution to be installed in Germany. IBA E-beam technologies enable various industries to be significantly more resilient and environmentally friendly by avoiding toxic chemicals and radioactive materials, and their associated waste, safety issues and hazards. Primarily driven by the conversion of a product portfolio from EtO to E-beam sterilization, this investment marks an important step in accelerating the adoption of IBA’s E-beam technology and the transition towards...

Author: Customer Service

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals